Drugs / TC-110 T Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04323657 | Mar 2020 → Feb 2023 | acute lymphoblastic leukemia, follicular lymphoma, mantle cell lymphoma, primary mediastinal large B-cell lymphoma | TCR2 Therapeutics | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TC-110 T Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04323657 ↗ |
| Modality | Cell therapy | “TC-110 T cells are a novel cell therapy” NCT04323657 ↗ |
| Target | CD19 | “recognizes human CD19” NCT04323657 ↗ |